Psyence Biomedical Secures Extension To Meet Nasdaq Compliance Standards
Psyence Biomedical Ltd. (NASDAQ:PBM) has successfully obtained an extension from the Nasdaq Hearings Panel, giving the company until December 31, 2024, to meet the exchange’s continued listing requirements. The decision, reached after a hearing on October 31, allows the company to remain listed while implementing measures to comply with Nasdaq’s rigorous benchmarks.
Psyence Biomed presented a comprehensive plan to address key requirements, including the $1 minimum bid price, a $1 million market value of publicly held shares and $2.5 million in minimum stockholders’ …